Using nanoscale particles to heal tissue damage
Official title: Therapeutic nanoscale matrimeres
Funded at University of Illinois at Chicago · NIH-11078798 · Data updated 2026-11-12
This study is testing a new treatment using tiny particles to help heal damaged blood vessel cells, which could help people with issues like swelling and tissue problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | April 1, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $402,946 |
| NIH project number | 5R01EB034507-03 |
| Project ID | NIH-11078798 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals suffering from conditions that lead to endothelial dysfunction or tissue injury, such as those with chronic inflammatory diseases or injuries.
✕Less likely to help
Patients with stable endothelial function or those not experiencing tissue injury may not benefit from this research.
What this research studies
This research investigates a new type of nanoparticle, called matrimeres, which are designed to restore the function of endothelial cells that have been damaged due to tissue injury. The approach focuses on delivering specific matrix molecules that are crucial for cell signaling and maintaining the integrity of blood vessels. By utilizing naturally secreted nanoparticles from mesenchymal stromal cells, the research aims to activate endothelial cells and repair the leaky barriers that can lead to serious complications like edema and tissue fibrosis. Patients may benefit from this innovative treatment if it proves effective in restoring normal tissue function.
Why it matters
Potential benefit: If successful, this research could provide a novel therapeutic approach to treat various conditions associated with tissue injury and vascular dysfunction.
How similar studies have gone: While the concept of using nanoparticles for tissue repair is gaining traction, this specific approach with matrimeres is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Shin, Jae-Won — University of Illinois at Chicago
- Study coordinator: Shin, Jae-Won
Related research
Other NIH-funded projects on the same topics.
-
MSC Secretome Eye Drops to Speed Healing of Corneal Wounds
A new eye drop made from stem cell–secreted factors is being tested to help adults with non-healing corneal wounds recover vision faster.
-
UIC Center for Healthy Work
A national program led by UIC aims to improve the health and well-being of workers through collaborative research and practical solutions.
-
Coordinated Oral Health Promotion for Chicago Kids
A long-running study in Chicago is following children and their caregivers to find ways to reduce tooth decay and improve daily life for families.
-
Targeting p38 MAPK to slow ALS-related axonal damage
Aims to block a specific brain-wide signaling pathway (p38 MAPK) to reduce nerve damage in people with various genetic forms of ALS.
-
Precision nanomedicine to calm inflammation and protect bone in gum disease
A new, targeted nanomedicine approach aims to reduce gum inflammation and prevent bone loss in adults with periodontal disease.
-
Role of DPP in Dental Pulp Stem Cells and their Regenerative Potential
A project explores how a natural tooth protein helps dental pulp stem cells repair and regenerate the tooth’s inner tissue.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.